Skip to content
2000
Volume 21, Issue 5
  • ISSN: 1573-4110
  • E-ISSN: 1875-6727

Abstract

Background and Objective

Pharmaceutical companies must adhere to rules established by regulatory agencies in order to monitor pharmaceutical products for nitrosamine contamination. One type of nitrosamine that can arise during the manufacture of the drug’s formulation and substance is N-Nitroso Tofacitinib. One pollutant that causes cancer is nitrosamines. Controlling the amount of nitrosamines in pharmaceuticals and medical supplies is essential. In this study, we devised a straightforward, sophisticated LC-MS/MS approach to analyse N-Nitroso Tofacitinib present in Tofacitinib tablets.

Materials and Methods

Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) experiments were optimised on Jade C18 (5 µ, 150 x 4.6 mm), solvent mixture was operated in gradient program using 10 mM ammonium acetate pH 3.2 and acetonitrile with 1.0 mL flow rate. Mass transition (m/z) 275.3/149.1, 275.3 /147.0, and 275.3/82.1 are used.

Results

The range of linearity is 0.7 - 20.0 ng/mL, with of 0.9952. The Lowest Detection (LOD) and quantification (LOQ) were 0.7 ng/mL and 1.0 ng/mL respectively. The recovery repeatability was found to be within the specified range.

Conclusion

The new approach proved effective for quantifying N-Nitroso Tofacitinib impurity in Tofacitinib Tablet samples, indicating that it could be applied for regular analysis.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cac/10.2174/0115734110304169240705112652
2024-07-15
2025-10-02

  • From This Site

    /content/journals/cac/10.2174/0115734110304169240705112652
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Recommended Acceptable Intake Limits for Nitrosamine Drug Substance Related Impurities (NDSRIs)Guidance for Industry, U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation.2023Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/updated-information-recommended-acceptable-intake-limits-nitrosamine-drug-substance-related
  2. Control of Nitrosamine Impurities in Human Drugs Guidance for IndustryU.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), February 2021, Pharmaceutical Quality/ Manufacturing Standards/ Current Good Manufacturing Practice (CGMP).2021Available from: https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations
  3. TrickerA.R. PreussmannR. Carcinogenic N-nitrosamines in the diet: occurrence, formation, mechanisms and carcinogenic potential.Mut. Res.Genet. Toxicol.19912593-4277289
     [Google Scholar]
  4. BayneA.C.V. MisicZ. StemmlerR.T. WittnerM. FrerichsM. BirdJ.K. BesheerA. N-nitrosamine mitigation with nitrite scavengers in oral pharmaceutical drug products.J. Pharm. Sci.202311271794180010.1016/j.xphs.2023.03.02237023856
     [Google Scholar]
  5. LiK. RickerK. TsaiF.C. HsiehC.J. OsborneG. SunM. MarderM.E. ElmoreS. SchmitzR. SandyM.S. estimated cancer risks associated with nitrosamine contamination in commonly used medications.Int. J. Environ. Res. Public Health20211818946510.3390/ijerph1818946534574388
     [Google Scholar]
  6. National Toxicology ProgramDepartment of Health and Human Services. 15th Report on Carcinogens: Nitrosamines.2021Available from: https://ntp.niehs.nih.gov/ ntp/roc/content/profiles/nitrosamines.pdf
  7. International Pharmaceutical Excipients Council (IPEC) FederationThe Role of Excipients in Determining N-Nitrosamine Risks for Drug Products.2022Available from: https://www.ipec-europe.org/uploads/publications/202203-if-nitrosamines-positionpaper-final-1646123452.pdf
  8. U.S. Food and Drug AdministrationControl of Nitrosamine Impurities in Human Drugs: Guidance for Industry. 2020. Report number: FDA-2020-D-1530.2020Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/control-nitrosamine-impurities-human-drugs
  9. MoserJ. AshworthI.W. HarrisL. HillierM.C. NandaK.K. ScrivensG. N-nitrosamine formation in pharmaceutical solid drug products: Experimental observations.J. Pharm. Sci.202311251255126710.1016/j.xphs.2023.01.02736736774
     [Google Scholar]
  10. BoetzelR. SchlingemannJ. HickertS. KornC. KocksG. LuckB. BlomG. HarrisonM. FrançoisM. AllainL. WuY. BousrafY. A nitrite excipient database: A useful tool to support N-nitrosamine risk assessments for drug products.J. Pharm. Sci.202311261615162410.1016/j.xphs.2022.04.01635500671
     [Google Scholar]
  11. NandaK.K. TignorS. ClancyJ. MarotaM.J. AllainL.R. D’AddioS.M. Inhibition of N-nitrosamine formation in drug products: a model study.J. Pharm. Sci.2021110123773377510.1016/j.xphs.2021.08.01034400183
     [Google Scholar]
  12. AkkarajuH. TatiaR. ManeS.S. KhadeA.B. DengaleS.J. A comprehensive review of sources of nitrosamine contamination of pharmaceutical substances and products.Regul. Toxicol. Pharmacol.202313910535510.1016/j.yrtph.2023.10535536792049
     [Google Scholar]
  13. WitkowskaA.B. WołczyńskaA. Lis-CieplakA. StolarczykE.U. Development and validation of LC-MS/MS method for the determination of 1-methyl-4-nitrosopiperazine (MNP) in multicomponent products with rifampicin—analytical challenges and degradation studies.Molecules20232821740510.3390/molecules2821740537959824
     [Google Scholar]
  14. DiabS. FerriniP. DomineyA.P. WhitingM.P. WickensJ.R. AshworthI.W. RaineyT.J. Investigation of the formaldehyde-catalyzed nnitrosation of dialkyl amines: an automated experimental and kinetic modelling study using dibutylamine.J Pharm Sci202411361624163510.1016/j.xphs.2024.01.017
     [Google Scholar]
  15. ParfantT.P. SkubeT. RoškarR. A robust analytical method for simultaneous quantification of 13 low-molecular-weight N-Nitrosamines in various pharmaceuticals based on solid phase extraction and liquid chromatography coupled to high-resolution mass spectrometry.Eur J Pharm Sci2024192106663310.1016/j.ejps.2023.106633
     [Google Scholar]
  16. WichitnithadW. NantapholS. NoppakhunsomboonK. RojsitthisakP. An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals.Saudi Pharm. J.202331229531110.1016/j.jsps.2022.12.01036942272
     [Google Scholar]
  17. IanW. Approaches and considerations for the investigation and synthesis of N-nitrosamine drug substance-related impurities (NDSRIs).Org. Process Res. Dev.202327101784179110.1021/acs.oprd.3c00084
     [Google Scholar]
  18. NakkaS. KatariN.K. MuchakayalaS.K. JonnalagaddaS.B. Manabolu SuryaS.B. Synthesis and trace-level quantification of mutagenic and cohort-of-concern ciprofloxacin nitroso drug substance-related impurities (NDSRIs) and other nitroso impurities using UPLC-ESI-MS/MS─method optimization using i-optimal mixture design.ACS Omega2024988773878810.1021/acsomega.3c0517038434810
     [Google Scholar]
  19. VenkateswaraP. RaoV. AnuradhaD. Ramachandran bandC.V. Development and validation of stability indicating RP-HPLC Method for quantitative estimation of tofacitinib in tofacitinib tablets dosage form.J. Pharmac. Res. Int.20223457162610.9734/jpri/2022/v34i577255
     [Google Scholar]
  20. SV.K. DhimanV. GiriK.K. SharmaK. ZainuddinM. MullangiR. Development and validation of a RP‐HPLC method for the quantitation of tofacitinib in rat plasma and its application to a pharmacokinetic study.Biomed. Chromatogr.20152991325132910.1002/bmc.342625622797
     [Google Scholar]
  21. N-Nitroso Tofacitinib Impurity.Available from: https://synzeal.com/en/n-nitroso-tofacitinib-impurity
  22. N-Nitroso Tofacitinib.Available from: https://veeprho.com/impurities/tofacitinib-nitroso-impurity
  23. DimitriosA. Treatment patterns and effectiveness of tofacitinib in patients initiating therapy for rheumatoid arthritis: results from the corevitas rheumatoid arthritis registry.J Rheumatol202451545246110.3899/jrheum.2023‑0752
     [Google Scholar]
  24. KamalShahed ShengWei Lo McCallSamantha RodriguesBeverly TsoiAndrew H. SegalJonathan P. Unveiling the potential of JAK inhibitors in inflammatory bowel disease.Biologics20244217718610.3390/biologics4020012
     [Google Scholar]
  25. CaiW. TongR. SunY. YaoY. ZhangJ. Comparative efficacy of five approved Janus kinase inhibitors as monotherapy and combination therapy in patients with moderate-to-severe active rheumatoid arthritis: A systematic review and network meta-analysis of randomized controlled trials.Front. Pharmacol.202415138758510.3389/fphar.2024.138758538725657
     [Google Scholar]
  26. van der HeijdeD. StrandV. TanakaY. KeystoneE. KremerJ. ZerbiniC.A.F. CardielM.H. CohenS. NashP. SongY.W. TegzováD. GrubenD. WallensteinG. ConnellC.A. FleischmannR. Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: clinical efficacy, radiographic, and safety outcomes from a twenty‐four–month, phase III Study.Arthritis Rheumatol.201971687889110.1002/art.4080330666826
     [Google Scholar]
  27. TesserJ. GülA. OlechE. OelkeK. LukicT. KwokK. EbrahimA. Efficacy and safety of tofacitinib in patients with rheumatoid arthritis by previous treatment: post hoc analysis of phase II/III trials.Arthritis Res. Ther.202325121410.1186/s13075‑023‑03154‑z37919780
     [Google Scholar]
  28. CohenS.B. TanakaY. MarietteX. CurtisJ.R. LeeE.B. NashP. WinthropK.L. Charles-SchoemanC. ThirunavukkarasuK. DeMasiR. GeierJ. KwokK. WangL. RieseR. WollenhauptJ. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.Ann. Rheum. Dis.20177671253126210.1136/annrheumdis‑2016‑21045728143815
     [Google Scholar]
  29. Di BenedettoP. RuscittiP. BerardicurtiO. PanzeraN. GraziaN. Di Vito NolfiM. Di FrancescoB. NavariniL. MauriziA. RucciN. TetiA.M. ZazzeroniF. GugginoG. CicciaF. DoloV. AlesseE. CiprianiP. GiacomelliR. Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis.Arthritis Res. Ther.202123121310.1186/s13075‑021‑02587‑834391476
     [Google Scholar]
  30. ChenY. GongF.Y. LiZ.J. GongZ. ZhouZ. MaS.Y. GaoX.M. A study on the risk of fungal infection with tofacitinib (CP-690550), a novel oral agent for rheumatoid arthritis.Sci. Rep.201771677910.1038/s41598‑017‑07261‑128754958
     [Google Scholar]
  31. OrsoliniG. BertoldiI. RossiniM. Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement.Clin. Rheumatol.202039372773610.1007/s10067‑020‑04930‑x31970549
     [Google Scholar]
  32. MaC. JairathV. Vande CasteeleN. Pharmacology, efficacy and safety of JAK inhibitors in Crohn's disease.Best Pract Res Clin Gastroenterol201938-3910160610.1016/j.bpg.2019.03.002
     [Google Scholar]
  33. López-SanrománA. Juan V.E. EugeniD. Pharmacology and safety of tofacitinib in ulcerative colitis.Gastroenterología y Hepatología2021441394810.1016/j.gastre.2020.04.007
     [Google Scholar]
  34. Available from: https://www.pfizermedicalinformation.com/en-us/xeljanz/clinical-pharmacology
  35. EugeniuszJ. Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology.Reumatologia201856420321110.5114/reum.2018.77971
     [Google Scholar]
  36. Tofacitinib.Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Tofacitinib
  37. CSO40197-N-Nitroso-Tofacitinib-Amine-Impurity.Available from: https://www.clearsynth.com/CSO40197-N-Nitroso-Tofacitinib-Amine-Impurity
  38. WuX. ZengX. WangL. HangT. SongM. Identification of related substances in tofacitinib citrate by LC-MS techniques for synthetic process optimization.J. Pharm. Biomed. Anal.2017143172510.1016/j.jpba.2017.05.01228549242
     [Google Scholar]
  39. SharmaK. GiriK. DhimanV. DixitA. ZainuddinM. MullangiR. A validated LC‐MS/MS assay for simultaneous quantification of methotrexate and tofacitinib in rat plasma: application to a pharmacokinetic study.Biomed. Chromatogr.201529572273210.1002/bmc.334825298296
     [Google Scholar]
  40. MuellerTim Tim Mueller, Site Management-Analytical, Patrik Appelblad, Senior Principal Scientist Millipore Sigma, Quantitative Analysis of Nitrosamine Impurities by LC-MS Methods from the United States Pharmacopeia.Available from: https://www.sigmaaldrich.com/PK/en/technical-documents/technical-article/pharmaceutical-and-biopharmaceutical-manufacturing/small-molecules-analysis-quality-control/quantitative-analysis-of-nitrosamine-impurities
  41. Liquid Chromatography-Electrospray Ionization-High Resolution Mass Spectrometry (LC-ESI-HRMS) Method for the Determination of Nitrosamine Impurities in Metformin Drug Substance and Drug Product, USFDA.2020Available from: https://www.fda.gov/media/138617/download
  42. Sanket Chiplunkar, Dheeraj Handique, Prashant Hase, Durvesh Sawant, Nitish Suryawanshi Aseem Wagle, Rahul Dwivedi, Jitendra Kelkar and Pratap Rasam, Shimadzu Analytical (India) Pvt. Ltd. Trace Level Quantitation of 6 Nitrosamines in Metformin API by Dynamic Headspace GC-MS/MS. Application News from Shimadzu Excellence in Science.2020Available from: https://www.shimadzu.com/an/sites/shimadzu.com.an/files/pim/pim_document_file/applications/application_note/14137/06-saip-084-gc-025-en.pdf
  43. Hemant Kesarkar, Sanket Chiplunkar, Prashant Hase, Durvesh Sawant, Aseem Wagle, Rahul Dwivedi, Dheeraj Handique, Pratap Rasam and Jitendra Kelkar Shimadzu Analytical (India) Pvt. Ltd. Ultra-Sensitive Dynamic Headspace GC-MS/MS Method for Trace Level Quantitation of Nitrosamines in Deferiprone API. Application News from Shimadzu Excellence in Science.2020Available from: https://www.shimadzu.com.sg/an/sites/shimadzu.com.sg.an/files/ultra-sensitive-dynamic-headspace-gc-ms-ms-method-for-trace-level-quantitation-of-nitrosamines-in-deferiprone-api.pdf
  44. Available from: https://vitalflux.com/interpreting-f-statistics-in-linear-regression-formula-examples/
  45. Control of Nitrosamine Impurities in Human Drugs Guidance for Industry, U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) February 2021 Pharmaceutical Quality/ Manufacturing Standards/ Current Good Manufacturing Practice (CGMP) Revision 1.2021Available from: https://www.fda.gov/media/141720/download
  46. MikhailK. Development and validation of four nitrosamine impurities determination method in medicines of valsartan, losartan, and irbesartan with HPLC-MS/MS (APCI).Iran. J. Pharmac. Res.202120354155210.22037/ijpr.2021.115102.15195
     [Google Scholar]
  47. Agilent Technologies.Available from: https://www.agilent.com/cs/library/applications/Nitrosamine%20and%20Mutagenic%20 Impurities%20Application%20Guide.pdf
  48. European Medicines AgencyICH M7 Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk - Scientific guideline.2018Available from: https://www.ema.europa.eu/en/ich-m7-assessment-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit-potential#current-effective-version–section
  49. EPAU.S. EPA Method 521: Determination of Nitrosamines in Drinking Water by Solid Phase Extraction (SPE) and Capillary Column Gas Chromatography with Large Volume Injection and Chemical Ionization Tandem Mass Spectrometry (MS/MS).Version 1.0.Cincinnati, OhioNational Exposure Research Laboratory2004
     [Google Scholar]
  50. Combined Direct Injection N-Nitrosodimethylamine (NDMA), N-Nitrosodiethylamine (NDEA), N-Nitrosoethylisopropylamine (NEIPA), N-Nitrosodiisopropylamine (NDIPA), and N-Nitrosodibutylamine (NDBA) Impurity Assay by GC-MS/MS.2019Available from: https:// www.fda.gov/media/123409/download
  51. Combined Headspace N-Nitrosodimethylamine (NDMA).2019Available from: https://www.fda.gov/media/124025/
  52. RapidFire-MS/MS method.2019Available from: https://www.fda.gov/media/125477/
  53. Available from: https://www.fda.gov/drugs/drugsafety-and-availability/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan#interimlimits2
  54. Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS) Method for the Determination of Six Nitrosamine Impurities in ARB Drugs.2019Available from: https://www.fda.gov/media/125478/download
  55. U.S. Environmental Protection Agency (EPA)SW-846 Test Method 8070A: Nitrosamines by Gas ChromatographyUnited States Environmental Protection Agency1996Available from: https://www.epa.gov/hw-sw846/sw-846-test-method-8070a-nitrosamines-gas-chromatography
    [Google Scholar]
  56. DesfontaineV. GuillarmeD. FrancotteE. NovákováL. Supercritical fluid chromatography in pharmaceutical analysis.J. Pharm. Biomed. Anal.2015113567110.1016/j.jpba.2015.03.00725818887
     [Google Scholar]
  57. HuC.W. ShihY.M. LiuH.H. ChiangY.C. ChenC.M. ChaoM.R. Elevated urinary levels of carcinogenic N- nitrosamines in patients with urinary tract infections measured by isotope dilution online SPE LC–MS/MS.J. Hazard. Mater.201631020721610.1016/j.jhazmat.2016.02.04826937867
     [Google Scholar]
  58. BharateS.S. Critical analysis of drug product recalls due to nitrosamine impurities.J. Med. Chem.20216462923293610.1021/acs.jmedchem.0c0212033706513
     [Google Scholar]
  59. SampathK. ReddyG. Stability indicating HPLC method for the quantification of tofacitinib citrate and its related substancesDer Pharma Chemica2014621119
     [Google Scholar]
  60. GorantlaS. SahaR.N. SinghviG. Design of experiment-driven stability-indicating RP-HPLC method for the determination of tofacitinib in nanoparticles and skin matrix.Fut. J. Pharmac. Sci.20217118010.1186/s43094‑021‑00325‑0
     [Google Scholar]
  61. WhiteC.M. Understanding and Preventing ( N -Nitrosodimethylamine) NDMA Contamination of Medications.Ann. Pharmacother.202054661161410.1177/106002801989222231771343
     [Google Scholar]
  62. ZmysłowskiA. KsiążekI. SzterkA. N-nitrosodimethylamine contamination in the metformin finished products.Molecules20202522530410.3390/molecules2522530433202951
     [Google Scholar]
  63. ShaikK.M. SarmahB. WadekarG.S. KumarP. Regulatory Updates and Analytical Methodologies for Nitrosamine Impurities Detection in Sartans, Ranitidine, Nizatidine, and Metformin along with Sample Preparation Techniques.Crit. Rev. Anal. Chem.20225215371Epub 2020 Jul 21.10.1080/10408347.2020.178837532691615
     [Google Scholar]
  64. CharooN.A. AliA.A. BuhaS.K. RahmanZ. lesson learnt from recall of valsartan and other angiotensin II receptor blocker drugs containing NDMA and NDEA impurities.AAPS PharmSciTech201920516610.1208/s12249‑019‑1376‑130989447
     [Google Scholar]
  65. ShaikhT. GosarA. SayyedH. Nitrosamine impurities in drug substances and drug products.J. Pharm. Pract.202024857
     [Google Scholar]
  66. Tofacitinib Dosage.Available from: https://www.drugs.com/dosage/tofacitinib.html
  67. EMA/409815/2020 Rev.17 Corr, Nitrosamines EMEA-H-A5(3)-1490 - QA Art. 5(3) Implementation, QA10, revision 17, EMA/409815/2020.2023Available from: https://www.ema.europa.eu/en/documents/referral/nitrosamines-emea-h-a53-1490-questions-answers-marketing-authorisation-holders-applicants-chmp-opinion-article-53-regulation-ec-no-726-2004-referral-nitrosamine-impurities-human-medicinal-products_en.pdf
  68. Available from: https://vitalflux.com/interpreting-f-statistics-in-linear-regression-formula-examples/
  69. QiongW. Er-minB. YuntianBi. YandingS. Simultaneous determination of tofacitinib and its principal metabolite in beagle dog plasma by UPLC-MS/MS and its application in pharmacokinetics.Arab.J. Chem.2022151103514
     [Google Scholar]
  70. WangX. JinB. WangZ. GuoK. ZhangT. MaC. Determination of enantiomer in tofacitinib citrate using reversed-phase chiral high-performance liquid chromatography.Separations20241138910.3390/separations11030089
     [Google Scholar]
  71. SchmidtsdorffS. SchmidtA.H. Simultaneous detection of nitrosamines and other sartan-related impurities in active pharmaceutical ingredients by supercritical fluid chromatography.J. Pharm. Biomed. Anal.201917415116010.1016/j.jpba.2019.04.04931174128
     [Google Scholar]
  72. JirešJ KalášekS GibalaP RudovskýJ DoušaM KubelkaT ŘezankaP Insight into the formation of N-nitrosodimethylamine in metformin products.J Pharm Biomed Anal.202120195
     [Google Scholar]
/content/journals/cac/10.2174/0115734110304169240705112652
Loading
An Efficient LC-MS/MS Method for Determining N-nitroso Tofacitinib Toxicity In the Tablet Form
Current Analytical Chemistry 21, 521 (2025); https://doi.org/10.2174/0115734110304169240705112652
/content/journals/cac/10.2174/0115734110304169240705112652
/content/journals/cac/10.2174/0115734110304169240705112652
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): ESI (electron spray ionization) mode; LC-MS/MS; mass transition; method validation; MRM (multiple reaction mode); N-nitroso tofacitinib; nitrosamines; parent ion; product ion; quantitation; tofacitinib

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test